search
Back to results

High Flow Nasal Oxygen and Acute Left Heart Failure (HFNO)

Primary Purpose

Heart Failure, Noninvasive Ventilation, Oxygen Therapy

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
High Flow Nasal Oxygen
Non-invasive Ventilation
Sponsored by
Nanjing Jiangbei People's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure focused on measuring High Flow Nasal Oxygen, Non-invasive Ventilation, Acute Left Heart Failure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • (1) Clinical diagnosis of acute left heart failure
  • (2) The patient receives invasive ventilation for more than 24 hours
  • (3) Must pass spontaneous breathing trials
  • (4) Patient's next of kin agrees to sign the informed consent.

Exclusion Criteria:

  • (1) Chronic Obstructive Pulmonary Disease (COPD)
  • (2) Disturbance of consciousness
  • (3)Bulbar paralysis, dysphagia
  • (4) Facial deformity
  • (5) Terminal tumor
  • (6) Neuromuscular disease

Sites / Locations

  • Nanjing Jiangbei People's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

HFNO group/Group A

NIV group/Group B

Arm Description

The patients should receive the treatment of high flow nasal oxygen immediately after extubation.

The patients should receive the treatment of non-invasive Ventilation immediately after extubation.

Outcomes

Primary Outcome Measures

re-intubation rate within 48 hours

Secondary Outcome Measures

Mortality
Hospitalization time
The length of ICU stay
blood gas analysis

Full Information

First Posted
July 2, 2018
Last Updated
April 7, 2022
Sponsor
Nanjing Jiangbei People's Hospital
Collaborators
Jiangsu Provincial People's Hospital, Jiangsu Province Hospital of Traditional Chinese Medicine, NanJing PLA 81 Hospital, Nanjing Chest Hospital, Mingji Hospital, Meishan Traditional Chinese Medicine Hospital, Nanjing LuHe People's Hospital, Nanjing Pukou Center Hospital, Thank Inn Chain Hotel Jiangsu Nanjing Lishui People's Hospital, Nanjing Gaochun People's Hospital, The First Affiliated Hospital with Nanjing Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT03607357
Brief Title
High Flow Nasal Oxygen and Acute Left Heart Failure
Acronym
HFNO
Official Title
The Effect of Post-extubation High Flow Nasal Oxygen in Patients With Acute Left Heart Failure: a Clinical Multi-center Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
May 10, 2018 (Actual)
Primary Completion Date
May 26, 2021 (Actual)
Study Completion Date
June 28, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nanjing Jiangbei People's Hospital
Collaborators
Jiangsu Provincial People's Hospital, Jiangsu Province Hospital of Traditional Chinese Medicine, NanJing PLA 81 Hospital, Nanjing Chest Hospital, Mingji Hospital, Meishan Traditional Chinese Medicine Hospital, Nanjing LuHe People's Hospital, Nanjing Pukou Center Hospital, Thank Inn Chain Hotel Jiangsu Nanjing Lishui People's Hospital, Nanjing Gaochun People's Hospital, The First Affiliated Hospital with Nanjing Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Acute left heart failure (ALHF) is a sudden attack or deterioration of abnormal left heart function, which may impair myocardial contractility and increase cardiac loading, further result in decreased cardiac output, abrupt elevation of pulmonary and systemic circulation pressure, consequently trigger in acute pulmonary congestion, acute pulmonary edema and cardiac shock . Hypoxia and severe dyspnea may pose fatal threats for the patients suffered from ALHF should be alleviated as soon as possible, and thus oxygen therapy and ventilation support are regarded as important therapeutic measures for these patients. According to 2017 Chinese College of Emergency Physicians(CCEP) acute heart failure clinical guideline, invasive ventilation should be recommended to those patients whose symptoms still get worsening despite timely treatments. Intubation may increase the risks of infection and multiple organ failure, so timely extubation contributes to reduce the duration of mechanical ventilation and the rate of complications. But if extubation failure occurs, the patient often requires re-intubation that may induce the outset of complications, extend the length of stay and increase mortality. Heart failure proves to be high risk factor for extubation failure on the basis of previous studies. It is recommended to apply sequential non-invasive ventilation (NIV) if the patient receiving invasive ventilation for more than 24 hours and having high risk for extubation failure on the basis of 2017 American Thoracic Society(ATS) clinical guideline. It is worthy to note that NIV has many shortcomings, for example, it may induce dry oropharyngeal cavity, skin injury caused by mask oppression, gaseous distention, vomiting, respiratory aspiration, air leak, drying sputum, difficulty in coughing up phlegm and claustrophobia. As an emerging technology, high flow nasal oxygen (HFNO) has many advantages in airway humidification, tolerance and compliance which also can effectively improve pulmonary oxygenation function of patients with respiratory failure. Which therapeutic measure should be recommended for the patients with ALHF after extubation, NIV or HFNO? It is still unclear according to the latest management guidelines. So one perspective study will be launch to compare the difference between HFNO-group patients with NIV-group patients in re-intubation rate within 48 hours, oxygenation index, length of ICU stay, total hospital stay, mortality and compliance for evidence-based medicine.
Detailed Description
The anticipated number of patient subjects will reach 120 in the study. The patient's condition should be informed to his/her next of kin and then agree to signs the informed consent. When passing spontaneous breathing trials and removing tracheal tube, the patients should be divided into two groups by random digital table. Group A/HFNO group: the patients should receive the treatment of high flow nasal oxygen immediately after extubation. The initial flow speed was set at 30L/min and increased at 5L/min in titrated type until the patient feels uncomfortable. The temperature was set at 37℃. The fraction of inspiration O2 was set in accordance with specific condition of patient to insure oxygen saturation more than 95%. Group B/NIV group: the patients should receive the treatment of non-invasive ventilation immediately after extubation. The initial pressure are set at a lower level (inspiratory pressure: 6-8cmH2O, expiratory pressure: 4cmH2O) and adjusted to a suitable level in 10-20min. The fraction of inspiration O2 was set in accordance with specific condition of patient to insure oxygen saturation more than 95%. The criteria of successful extubation: the patient doesn't require re-intubation within 48 hours after extubation. The criteria of extubation failure: the patient needs re-intubation and ventilation support within 48 hours after extubation. (1) Investigators should keep a record of these patient's general condition, for instance, age, sex, diagnosis, Apache II score, treatment, etc.(2) Investigators should routinely detect clinical manifestation, ventilation parameters and physiological indices of the recruited patients. Elementary monitoring indicators consist of vital signs, oxygen saturation, ECG, tidal volume, breathing rate, inspiratory pressure, expiratory pressure and blood gas analysis. Blood gas analysis should be evaluated on an average of 12 hours, within the range of 48 hours after extubation.(3) Clinical prognosis of these patients should be recorded, including the rate of weaning failure, re-intubation rate, time for re-intubation, causes of re-intubation, duration of HFNO/HIV, length of ICU stay, hospitalization time and number of death.(4) The data of adverse effect derived from devices applied in the study should be recorded. HFNO group: dry nasal cavity, dry oropharyngeal cavity, dysphagia.HIV group: dry oropharyngeal cavity, skin injury caused by mask oppression, gaseous distention, vomiting, respiratory aspiration, air leak, drying sputum, difficulty in coughing up phlegm and claustrophobia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure, Noninvasive Ventilation, Oxygen Therapy
Keywords
High Flow Nasal Oxygen, Non-invasive Ventilation, Acute Left Heart Failure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
123 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HFNO group/Group A
Arm Type
Experimental
Arm Description
The patients should receive the treatment of high flow nasal oxygen immediately after extubation.
Arm Title
NIV group/Group B
Arm Type
Placebo Comparator
Arm Description
The patients should receive the treatment of non-invasive Ventilation immediately after extubation.
Intervention Type
Device
Intervention Name(s)
High Flow Nasal Oxygen
Intervention Description
The initial flow speed is set at 30L/min and increases at 5L/min in titrated type until the patient feels uncomfortable. The temperature is set at 37℃. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
Intervention Type
Device
Intervention Name(s)
Non-invasive Ventilation
Intervention Description
The values of initial pressure are set at a lower level (inspiratory pressure: 6-8cmH2O, expiratory pressure: 4cmH2O) and adjusted to a suitable level in 10-20min. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
Primary Outcome Measure Information:
Title
re-intubation rate within 48 hours
Time Frame
48 hours after extubation.
Secondary Outcome Measure Information:
Title
Mortality
Time Frame
28 days after joining the study.
Title
Hospitalization time
Time Frame
From date of randomization to the day when the patient discharges from any cause, assessed up to three months
Title
The length of ICU stay
Time Frame
From date of randomization to the day when the patient leaves ICU ward, assessed up to three months
Title
blood gas analysis
Time Frame
on an average of 12 hours, within the range of 48 hours after extubation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: (1) Clinical diagnosis of acute left heart failure (2) The patient receives invasive ventilation for more than 24 hours (3) Must pass spontaneous breathing trials (4) Patient's next of kin agrees to sign the informed consent. Exclusion Criteria: (1) Chronic Obstructive Pulmonary Disease (COPD) (2) Disturbance of consciousness (3)Bulbar paralysis, dysphagia (4) Facial deformity (5) Terminal tumor (6) Neuromuscular disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhenglong Ye, bachelor
Organizational Affiliation
Nanjing Jiangbei People's Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Nanjing Jiangbei People's Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210002
Country
China

12. IPD Sharing Statement

Learn more about this trial

High Flow Nasal Oxygen and Acute Left Heart Failure

We'll reach out to this number within 24 hrs